Ofloxaid OZ Tablet is a combination antibiotic formulation containing Ofloxacin 200 mg and Ornidazole 500 mg, indicated for the treatment of mixed bacterial and protozoal infections. Ofloxacin, a fluoroquinolone antibiotic, exerts its bactericidal effect by inhibiting bacterial DNA gyrase and topoisomerase IV, thereby preventing DNA replication and transcription. Ornidazole, a nitroimidazole derivative, exhibits potent activity against anaerobic bacteria and protozoa by disrupting DNA synthesis and causing strand breakage. This synergistic combination is effective in managing infections such as gastrointestinal infections, genitourinary tract infections, respiratory tract infections, skin and soft tissue infections, and certain protozoal infections including amoebiasis and giardiasis. Ofloxaid OZ is particularly useful in polymicrobial infections where both aerobic and anaerobic pathogens are implicated. The tablet should be administered as prescribed by a healthcare professional, with dosage adjustments based on the severity of infection, renal function, and patient response. Common side effects may include gastrointestinal disturbances, dizziness, and hypersensitivity reactions. Caution is advised in patients with a history of hypersensitivity to fluoroquinolones or nitroimidazoles, and it is contraindicated during pregnancy and lactation. Proper adherence to the prescribed regimen is essential to prevent resistance development and ensure therapeutic efficacy.